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ABSTRACT 
 
Mesenchymal stem cells (MSC) represent a promising therapeutic approach for 
neurological autoimmune diseases; previous studies have shown that treatment with 
bone marrow-derived MSC induces immune modulation and reduces disease severity in 
experimental autoimmune encephalomyelitis (EAE), an animal model of multiple 
sclerosis. 
Here we show that intravenous administration of adipose-derived MSC (ASC) before 
disease onset significantly reduces the severity of EAE and decreases spinal cord 
inflammation and demyelination by immune modulation. ASC preferentially home into 
lymphoid organs, but migrates also inside the central nervous system (CNS). Most 
importantly, administration of ASC in chronic established EAE significantly 
ameliorates the disease course and reduces both demyelination and axonal loss, and 
induces a Th2-type cytokine shift in T cells. Interestingly, a relevant subset of ASC 
expresses activated α4 integrins and adheres to inflamed brain venules in intravital 
microscopy experiments. Bioluminescence imaging confirms that α4 integrins control 
ASC accumulation in inflamed CNS. After penetration within EAE lesions, ASC 
induce a significant increase of the number of endogenous oligodendrocyte progenitors. 
As for the mechanisms responsible for such effect, we found that ASC cultures produce 
vascular endothelial growth factor, insulin growth factor-I, basic fibroblast growth 
factor, brain-derived growth factor and platelet-derived growth factor-AB both in basal 
condition and after inflammatory stimulus. Interestingly, these molecules are all 
involved in the proliferation of both oligodendrocyte precursors and ASC themselves. 
In conclusion, we show that ASC display clear therapeutic effect by a bimodal 
mechanism, by suppressing the autoimmune response in early phases of disease as well 
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as by inducing local neuro-regeneration by activating endogenous progenitors in 
animals with established disease.  
Overall our data suggest that ASC represent a valuable tool for stem cell-based therapy 
in chronic inflammatory diseases of the CNS. 
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INTRODUCTION 
 
MULTIPLE SCLEROSIS 
 
Etiology and pathogenesis of MS 
 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating autoimmune disease 
of the central nervous system (CNS) of unknown aetiology and heterogeneous clinical 
symptoms and course. 
The most frequent symptoms are weakness and/or sensory disturbances in one or more 
limbs, optic neuritis, ataxia, bladder dysfunction, fatigue and cognitive deficits 
(O'Connor,’02). The most common clinical pattern, affecting about 80% of patients, 
encompasses relapsing and remitting clinical signs and symptoms at the beginning of 
disease (RRMS), which are characterized by acute attacks followed by complete or 
partial recovery and a lack of disease progression in between two relapses. After 10–20 
years, the majority of these patients develop a progressive disease course (secondary 
progressive MS, SPMS) with creeping deterioration of mainly motor function of the 
lower limbs. Up to 15% of MS patients show disease progression from the beginning, 
which is defined as primary progressive MS (PPMS) and which most likely represents a 
slightly different underlying pathology with more diffuse demyelination and axonal 
damage and less inflammatory contribution (Weiner ’04; Hafler et al.,’07; Debouverie 
et al., 2008) (Figure 1).   
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                                            Figure 1: Clinical subtypes of MS 
 
Much has been done to understand the aetiology of MS, with a major focus on the role 
of the immune system. The autoimmune reaction has been shown to involve the 
activation of both T and B lymphocytes infiltrating the brain and the spinal cord. In 
general, T cell responses are beneficial and protect us against pathogens; however, their 
unrestrained activation can be deleterious and cause autoimmune diseases.   
Naive T cells differentiate into separate functional effector subsets specializing in 
producing cytokines in different combinations. Initially, two polarized subsets were 
described: T helper 1 (Th1) cells produce interferon-γ (IFN-γ), tumor necrosis factor-α 
(TNFα), and/or interleukin-2 (IL-2), and play a critical role in protection against 
intracellular pathogens. T helper 2 (Th2) cells, which instead produce IL-4, IL-5, IL-9, 
and IL-13, but not IFN-γ, are involved in protection against helminthes, as well as in 
allergic responses and modulating Th1-mediated inflammatory responses (Holmoy,’07; 
McFarland et al,’07).  
A more recently described subset of CD4+ effector Th cells has been named Th17, 
because of its ability to produce IL-17 in addition to other cytokines. Th17 cells 
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apparently protect against extracellular infections by gram-negative bacteria and fungi, 
partly by recruiting neutrophils. Differentiation of naive CD4+ T cells into Th1 cells 
requires IL-12, IFNγ, or both, whereas Th2 cells are polarized by IL-4 in the absence of 
IL-12 and IFN-γ, and Th17 cells require IL-23 for their terminal differentiation. 
Recently, it has been identified a minor subpopulation of CD4+ cells that selectively 
express forkhead box P3 (FoxP3) capable of preventing the development of 
autoimmunity, thus exerting a regulatory effect (Treg). Tregs seems to modulate both 
Th1 and Th2 effector responses during infection, as well as in models of autoimmunity 
and allergy; the impact of Tregs on Th17 responses in autoimmunity and infection 
requires more detailed study (O’Connor et al.,’09) (Figure 2). 
 
        Figure 2: Immunopathogenesis of MS (Holmoy et al.,’08). 
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It is important to understand the individual contributions of the various T cell subsets to 
disease progression to define suitable targets for future therapies. The activation of 
CD4+ autoreactive T cells are crucial events in the initial steps of the pathology: it was 
thought that acute lesions were initiated only by CD4+ Th1, but mounting evidence now 
indicates that also Th17 cells play a significant role in MS pathogenesis; some studies 
have shown that Th1 and Th17 cells have been implicated in the animal model of MS, 
experimental autoimmune encephalomyelitis (EAE), and have also been detected in 
brains of MS patients, especially in acute lesions  (Korn et al., 2007; Bettelli et al., 
2008; Tzartos et al., 2008). 
It has been suggested that myelin-specific auto-reactive IFN-γ secreting Th1 cells 
and/or IL-17 producing Th17 cells are primed in periphery by unknown factors 
(autoantigens or foreing, eg. viral), after which they migrate to CNS through ICAM-1, 
VCAM-1 and E-selectin mechanisms. Once antigen-specific T cells arrive in the CNS, they 
interact with local antigen presenting cells (APC) capable of presenting a MHC-peptide 
complex. In MS, there is reason to believe that the peptide presented by the local APC is a 
breakdown product of myelin and this molecular mimicry may trigger either an enhanced 
immune response against the bound antigen or down-regulation of immune response 
(anergy), depending on the type of signalling that results from the interactions between the 
surface co-stimulatory molecules and their ligands. In case of positive interaction, the 
activation leads to the production of pro-inflammatory cytokines such as IL-12, IFN-γ, 
TNF-α and IL-17,  that results in the proliferation of the Th1 and Th17 cells and ultimately 
in immune-mediated injury to myelin and oligodendrocytes. 
In case of anergy, T cells release a different subset of cytokines such as IL-1, IL-4 and IL-
10, which counteract pro-inflammatory cytokines leading to the proliferation of anti-
inflammatory CD4+ Th2 cells. Th2 cells may send anti-inflammatory signals to local APCs 
and stimulate pathologic or repair-enhancing antibody-producing cells. The balance 
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between pro-inflammatory and immunomodulating cytokines is important in regulating 
disease activity and an imbalance favouring pro-inflammatory cytokines may result in final 
demyelination, axonal loss and subsequent neurological disability (Sospedra and Martin, 
2005).              
Damage of the target tissue, the CNS in our case, is, however, most likely mediated by 
other components of the immune system, such as antibodies, complement and factors 
produced by innate immune cells. The observation that IgG are elevated in the 
cerebrospinal fluid (CSF) of MS patients has been the most important and earliest 
evidence suggesting an involvement of B cells and antibodies in the pathogenesis of 
MS. The role of the humoral immune response in MS pathogenesis is supported by 
several observations:  EAE studies have shown that B cells are involved in disease 
initiation (Raine et al., ’99) and can also modify disease phenotype and severity 
(Svennson et al.,’02); moreover, high numbers of chronically activated B cells, plasma 
cells and increased IgM and IgG are present in the CSF and meninges of MS patients. 
Furthermore, B-cell clonal expansion and oligoclonal IgG production can be detected in 
brain plaques and CSF from patients with MS (Colombo et al.,’00). 
Recent studies have suggested that the innate immune system also plays an important 
role both in the initiation and progression of MS by influencing the effector function of 
T and B cells (Weiner,’08). The effector cells, in turn, express cytokines and activation 
markers that further activate innate immune cells (Monney et al.,’02). 
Dendritic cells (DCs) are professional antigen presenting cells that play an important 
role in promoting activation and differentiation of naïve T cells. The interaction of DCs 
with T cells is crucial in determining T cell differentiation into either effector T cells 
(Th1, Th2 and Th17 cells) or regulatory T cells (natural and induced Tregs cells). DCs 
can also affect NK cells, promoting pro-inflammatory T cell responses in MS and are 
also involved in determination of the RR and SP disease phases (Gandhi et al.,’09). 
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Microglial cells comprise 10–20% of glial cells and are the most common immune cells 
in the CNS. Microglial cells are considered resident macrophages of the nervous 
system, being involved in phagocytosis, antigen presentation and production of 
cytokines (Benveniste,’97). Microglial cells are rapidly activated in response to injury, 
neuro-degeneration, infection, tumors and inflammation. Microglial/macrophage cell 
activation contributes to MS and EAE pathology through antigen presentation with 
MHC-II and costimulatory molecules (CD83 and CD40) and secretion of pro-
inflammatory cytokines. Persistent activation of microglial cells has also been observed 
in the chronic phase of relapsing-remitting EAE and a correlation has been observed 
between activated microglial cells and loss of neuronal synapses. In addition, 
macrophages and microglial cells are involved in demyelination and phagocytosis of 
the degraded myelin (Rasmussen et al.,’07). 
Natural killer (NK) cells contribute to both effector and regulatory functions of the 
innate immune system via their cytotoxic activity mainly against viral infected cells or 
tumor cells and through their ability to secrete different cytokines (Moretta et al.,’08). 
Several reports have highlighted the importance of NK–DC interactions during the 
early stages of the immune responses (Ferlazzo et al.,’02). NK cells can stimulate DC 
maturation and increase the amount of DC-produced cytokines (Gerosa et al.,’02; 
Piccioli et al.,’02). However, the actual role of NK cells in CNS autoimmunity is still 
not clear.                            
 
Besides the critical role of immune system in MS pathogenesis, it remains to be 
elucidated how the immune attack leads to neuronal damage. Probably, once in the 
perivascular space, autoreactive T cells get reactivated by local APCs, and thereby gain 
access to CNS parenchyma through glia limitans. Pro-inflammatory cytokines released 
by activated T cells and activated microglia lead to further inflammatory cell 
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recruitment, finally resulting in an aggressive immune attack against the myelin sheath. 
Following myelin disruption, unprotected axons were affected by metabolic 
dysfunction and  showed higher vulnerability to neurotoxic mediator, resulting in 
progressive and massive axonal degeneration (Herz et a.,’09).  
Remyelination processes are in most cases insufficient, leading to irreversible 
disability. Different factors account for this repair deficit: local inhibitors of the 
differentiation of oligodendrocyte progenitor cells (OPCs) or a defect in the recruitment 
of OPCs toward the demyelinated area may be involved in inefficient remyelination 
(Piaton et al.,’09).  
Although the disease course is highly variable, 50% of patients will not be able to walk 
independently within 15 years of onset. Current treatments for MS include 
immunomodulatory and immunosuppressive drugs. Interferon beta and glatiramer 
acetate reduce the number of relapses, but if these therapies are not successful or the 
disease develops into a progressive phase there are no effective treatments for 
modification of the course of the disease. Mitoxantrone showed the clinical progression 
of secondary progressive MS in a randomised clinical trial, although its long-term 
clinical effect is unknown. The limited effectiveness of these treatments justifies the 
assessment of alternative therapeutic strategies in patients with MS with aggressive 
clinical course (Blanco et al.,’05).  
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EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE)  
 
Due to the limited availability of human brain tissue during active disease, especially in 
early disease stages, a broad variety of animal models have been developed to get a 
deeper understanding of the molecular mechanisms and kinetics of neuronal cell death 
and axonal degeneration during inflammatory autoimmune CNS disease.  
EAE is possibly the best animal model to study autoimmune diseases and in particular 
demyelinating diseases of the CNS such as MS (Furlan et al.,’09).  
Today the most common forms of EAE are: 
1. active EAE induced by subcutaneous injection of an encephalitogenic peptide, 
mostly myelin oligodendrocyte glycoprotein (MOG)35-55 or proteolipid protein 
(PLP)139-151, which is emulsified in complete Freund’s adjuvant (CFA) containing 
mineral oil and Mycobacterium tuberculosis, followed by intraperitoneal injection of 
pertussis toxin; 
2. adoptive transfer EAE (AT-EAE) induced by intravenous injection of myelin-
reactive CD4+ Th1 lymphocytes into naïve animals (Gold et al.,’06; Mix et al.,’08). 
Depending upon the species, the antigen and the mode of sensitization, EAE may have 
a chronic relapsing (Figure 3 A) and a severe attack followed by incomplete recovery 
and a secondary progressive stage (Figure 3 B) course that mimics human MS.        
The classical picture of acute EAE is characterized by perivascular inflammation 
mainly represented by CD4+ and CD8+ T lymphocytes, macrophages within the spinal 
cord and less consistently in the brain and extensive demyelination, axonal and 
neuronal damage. 
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                              Figure 3: EAE clinical course (Furlan et al.’09) 
 
The environment exerts a major effect on EAE, leading to the activation of 
autoaggressive T cells which consequently home to the brain and induce disease. 
Activation state is the necessary prerequisite for T cells to migrate through the blood-
brain barrier (BBB) irrespective of their antigen specificity and the migration through 
the BBB requires the involvement of adhesion molecules on both T cells (LFA-1 and 
VLA-4) and endothelial cells (ICAM-1 and VCAM-1). Following migration, 
neuroantigen-specific CD4+ T cells are reactivated in situ by fragments of myelin 
antigens presented in the framework of MHC class II molecules on the surface of 
macrophages and microglia.  
These events are associated with the release of a vast amount of cytokines that could 
have a pro-inflammatory effect (TNF-α, TNF-β, IFN-γ and IL-12) and consequently a 
disease-promoting role, or anti-inflammatory cytokines (TGF-β, IL-10 and possibly IL-
4), which may protect from disease (Furlan et al ’09; Herz et al., ‘09). 
This immunopathological scenario make chronic EAE a suitable model to test 
therapeutic approaches which target simultaneously both inflammation and neuro-
degeneration. 
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The complexity of MS pathogenesis and the poor efficacy of approved therapies, 
challenged researchers to keep open minds and to develop future plans of attack from 
multiple fronts, as stem cells-based therapies. 
 
 
STEM CELLS 
Origin and characteristics  
Stem cells have captured the popular imagination with the promise of enhanced tissue 
repair, the treatment of degenerative diseases and even the amelioration of dysfunction 
associated with normal ageing. Stem cells are defined as cells that have the ability to 
renew themselves continuously and possess the ability to differentiate into many cell 
types. It is important to do some distinction in the wide and heterogeneous world of 
stem cells: stem cells are not homogeneous but exist instead as part of a developmental 
continuum.  
The most primitive of the cells, the embryonic stem cell, is totipotent. This cell has the 
potential to develop into a complete embryo, to form any type of cell, but this unique 
property is evanescent. It appears with fertilization of the egg and disappears by the 
time the embryo reaches the 4- to 8-cell stage. With subsequent divisions, embryonic 
stem cells lose the ability to generate an entire organism, however, they are capable of 
differentiating into cells present in all 3 embryonic germ layers,  ectoderm, mesoderm, 
and endoderm, and on this basis are called pluripotent.  
With subsequent divisions, cells become more and more restricted in their ability to 
differentiate into multiple lineages. They are then called multipotent and they are 
capable of forming a limited number of cell types. This is the property of adult stem 
cells, also referred to as somatic stem cells, which are able to self-renew during the 
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lifetime of the organism and to generate differentiated daughter cells. In the adulthood, 
tissues are in a perpetual state of flux under homeostatic conditions. Even in the 
absence of injury, they are continuously producing new cells to replace those that have 
worn out. For this reason, adult stem cells can be found in a metabolically quiescent 
state in most specialized tissues of the body, including the brain, bone marrow, liver, 
skin, and fat (Figure 4). 
                    
      
 
                                         Figure 4: Different stem cells 
 
 
Embrionic Stem Cells 
In 1981, pluripotent cells were found in the inner cell mass of the mouse embryo, and 
the term “embryonic stem cell” was coined (Martin et al.1981; Evans and Kaufman, 
1981). Embryonic stem cells (ESC) are derived from the blastocyst, the pre-
implantation embryo that develops 5 days after the fertilization of an egg by a sperm. It 
contains all the material necessary for the development of a complete human being. The 
inner mass of the blastocyst is composed of 30-34 cells that are referred as pluripotent 
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because they have the potential to produce all of the body’s cell types. ESC can be 
expanded in vitro for prolonged periods of time without loss of pluripotency.                                                                                       
The possible use of ESC in regenerative medicine is strongly limited, in addition to 
ethical considerations, by the observation that transplanted ESC lead to the induction of 
teratomas, formed by the uncontrolled growth of cells. Moreover, their clinical 
application is limited because ESC represent an allogenic resource and thus have the 
potential to evoke an immune response (Hipp et al.’08). 
           
                                    
Foetal Stem Cells 
An alternative source for ESC-based treatments may be represented by cells established 
from the foetus proper or from the supportive extra-embryonic structures (amniotic 
fluid, umbilical cord, Wharton’s jelly, amnion and placenta) (foetal stem cells; FSC). 
Several studies indicate that stem cells derived from these foetal sources exhibit many 
features of ESC regarding the expression of stem-cell markers and their self-renewal 
capacity, while their spectrum of differentiation potential, either in vivo and in vitro, 
recapitulates features of plasticity residing between the pluripotent ESC and the 
multipotent adult stem cells. Moreover, FSC do not seem to form teratomas (Pappa et 
al.,’09). Among foetal tissues, umbilical cord blood has served as a source of 
hematopoietic stem and progenitor cells, including mesenchymal stem cells, for 
successful repopulation of the blood cell system in patients with malignant and 
nonmalignant diseases or for further expansion. Umbilical cord blood stem cells 
(UCB-SC) exhibit replating efficiency indicative of self-renewal potential, as well as 
multi-differentiation potential (Broxmeyer HE, et al.,’02).   
 
 
 15 
Induced Pluripotent Stem Cells 
Ethical difficulties regarding the use of human embryos, as well as the problem of 
tissue rejection following transplantation have induced researchers to look for a way to 
circumvent these issues: in 2006 Takahashi and Yamanaka demonstrated the possibility 
to generate pluripotent cells directly from the patients’ own cells.  
Induced pluripotent stem cells (iPS) were first produced from somatic mouse cells and 
in 2007 from somatic human cells, after retroviral transduction with the four 
transcription factors Oct3/4, Sox2, c-Myc and Klf4. The generated iPS were 
remarkably similar to naturally-isolated pluripotent stem cells: morphology, cell surface 
antigenic markers, genes expression and capability of differentiation into fully 
differentiated tissues were similar to ESC.  
This has been cited as an important advancement in stem cell research, as it may allow 
researchers to obtain pluripotent stem cells, without the controversial use of embryos 
(Takahashi and Yamanaka,’06). 
 
In addition to ESC, FSC and iPS, tissue specific stem cells could be isolated from 
various tissues of more advanced developmental stage: 
 
Adult Stem Cells 
More restricted stem cells can also be obtained from a variety of adult tissues and could 
be indicated as adult or somatic stem cells (ASC). ASC tend to be a tissue specific, self-
renewing populations of cells which can differentiate into cell types associated with the 
organ system in which they reside; they are quite rare, on the order of 1 in 10,000 cells 
within the tissue of interest. Currently, it is known that niches of stem cells exist in 
many tissues, such as bone marrow, brain, liver, skin, skeletal muscle, the 
gastrointestinal tract, the pancreas, the eye, blood, fat and dental pulp (Hipp et al.,’08). 
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For many years, the general belief was that adult tissue-derived multipotent stem cells 
were developmentally restricted to the tissue where they reside. However, in the last 
years, several studies showed that some populations of adult stem cells endowed with 
the capacity to trans-differentiate into cells belonging to different germ layers, 
including neural cells (Bjornson et al.,’99). 
 
Neural Stem Cells 
Among ASC, multipotent neural stem cells (NSC) could represent an interesting tool in 
cell transplantation, especially in neurological disorders. 
NSC are an heterogeneous population of immature, self-renewing, multipotent, 
progenitor cells of adult mammalian CNS capable of driving neurogenesis and 
gliogenesis throughout adulthood within certain specialized regions of the brain (i.e. the 
sub-ventricular zone (SVZ), the olfactory bulb and the dentate gyrus of the 
hippocampus), which therefore behave as highly specialized tissue niches (Figure 5) 
(Gage,‘00). 
                                     
                      Figure 5: Neural stem cells; origin and differentiation. 
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Adult NSC can undergo extensive in vitro expansion upon epigenetic stimulation and 
possess the capacity to generate a progeny of differentiated functional daughter neural 
cells like neurons, oligodendrocytes and astrocytes (Kim et al.,’04).  
It has been recently shown that endogenous NSC may sustain neurogenesis and 
gliogenesis in response to several different injuries such as those occurring during 
inflammatory, ischemic, or traumatic events (Picard-Riera et al.,’02). These pathogenic 
events might trigger a cascade of cellular and molecular signals – possibly via the 
release of soluble mediators (e.g. cytokines, chemokines, metalloproteases, adhesion 
molecules, etc.) – that are capable of supporting neurogenesis and gliogenesis that, in 
turn, drive brain repair. In vivo experiments aiming at repairing injured CNS by 
transplanting multipotent adult NSC, have shown that these cells might survive to 
transplantation procedures within the host CNS, can display notable migratory 
properties from the site of grafting due to the expression of VLA-4, the counter-ligand 
of VCAM-I, and maintain their multipotency. Notably, NSC transplants did not induce 
tumor formation in immunodeficient mice, thus strongly suggesting that the 
tumorigenic potential in vivo of such a potent cell source is minimal. However, 
transplanted NSC might exert their therapeutic effect not only by differentiating into 
lineage-restricted daughter cells but continuing to release neurotrophic growth factors. 
This latter evidence suggests that NSC might repair brain damage also remaining in 
their undifferentiated state and acting as bystander regulators of neuron and/or 
oligodendrocyte rescuing via the constitutive or induced release of neurotrophic 
molecules (Pluchino et al.,’03-’05). Thus, in vitro cultivated NSC represent a reliable 
cell source for transplantation experiments. 
However, the invasiveness associated with harvesting of NSC and the small amount of 
cells that can be obtained may limit their clinical application. As the efforts to bring 
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experimental advances to the clinic are mounting, the source of these cells is becoming 
a crucial issue.  
A potential alternative to NSC is represented by mesenchymal stem cells (MSC).  
 
Mesenchymal Stem Cells 
Historically, bone marrow (BM) has been considered an elective source of adult stem 
cells. The adult bone marrow contains a heterogeneous population of cells including 
hematopoietic stem cells, macrophages, erythrocytes, fibroblasts, adipocytes and 
endothelial cells. In addition to these cell types, the bone marrow also contains a subset 
of non-hematopoietic stem cells which posses a multilineage potential, representing 
0,01-0,001% of total BM cells (Figure 6). 
           
 
                                               Figure 6:  Bone marrow cells 
 
The presence of this non-haematopoietic stem cells was first suggested by the 
observations of the German pathologist Clonheim 130 years ago. His work raised the 
possibility that BM may be the source of fibroblasts that deposit collagen fibres as part 
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of the normal process of wound repair. Evidence that BM contains cells that can 
differentiate into other mesenchymal cells, as well as fibroblasts is now available, 
starting with the work of Friedenstein and colleagues (Friedenstein et al.,’74). He 
described the isolation of large, polygonal, spindle-shaped, clonogenic cells in 
monolayer cultures, which he defined as colony-forming unit fibroblasts (CFU-Fs). 
CFU-F-derived stromal cells can serve as feeder layers for the culture of HSC and they 
can differentiate into adipocytes, chondrocytes and osteocytes both in vitro and after 
transfer in vivo (Prockop et al.’97).   
MSC have now been isolated from various sites other than BM, almost from every type 
of connective tissue,  and also in other tissues including, spleen, thymus, adipose tissue, 
amniotic fluid and so on. 
Since a specific and unique marker has not yet been identified, MSC could be defined 
according to 4 criteria:  
- MSC show he ability to proliferate in vitro as plastic-adherent cells; 
- MSC express CD29, CD44, CD71,  CD73, CD90, CD105, CD271 and Stro-1; 
The variable expression level of these markers that has been observed probably arises 
from species differences, tissue source and culture conditions. 
- MSC do not express the haematopoietic markers CD45, CD34 and CD14 and co-
stimulatory molecules CD80, CD86 and CD40; in addition, MSC do not express HLA 
class II antigens and therefore transplantation into an allogenic host may not require 
immunosuppression.  
In addition, another criteria  to identify supposed MSC population, is their  capacity to 
be induced to differentiate in vitro into chondrocyte, osteoblast and adipocyte 
(Dominici et al., ’06). 
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The rationale for the use of MSC in cell transplantation therapy is the consideration that 
these cells couple an immunomodulatory activity with the ability to penetrate into 
damaged tissue, where they could release trophic factor or undergoing trans-
differentiation resulting in directly regenerative effect. Probably the different relevance 
of these effects depends on the pathological conditions. 
 
The immunomodulatory effect of MSC has only been recently described, following the 
observation that BM-MSC, the largely studied population of MSC, strongly inhibited 
T-cell responses to mitogens and alloantigens. 
In vitro and in vivo studies indicate that BM-MSC exert their effect on T-cells 
activation, effector function and proliferation. Several studies have demonstrated BM-
MSC exert their effect preferentially on T-cell proliferation: in the presence of MSC, 
virtually no cell division could be detected within 72 hours (Glennie et al., ’05). BM-
MSC induced the arrest of T cells in the G0/G1 phase of the cell cycle, but do not 
promote T-cell apoptosis. Inhibition of T-cell proliferation by MSC has been reported 
to lead to decreased IFNγ production both in vitro and in vivo and to increased IL-4 
production by Th2 cells, which indicates a shift in T cells from a pro-inflammatory 
(IFNγ-producing) state to an anti-inflammatory (IL-4-producing) state.  
It has also been shown that MSC have immunomodulatory properties impairing CD8+ 
T-cell cytotoxicity and directly inducing the proliferation of regulatory T cells, a 
specialized subpopulation of T cells that suppress activation of the immune system and 
thereby help to maintain homeostasis and tolerance to self antigens. (Uccelli et al.’06-
’08; Tyndall et al.,’09). 
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               Figure 7: Immunomodulatory effect of BM-MSC (Uccelli et al.,’08) 
 
As regards the interaction between BM-MSC and B cells, several groups have 
demonstrated that MSC inhibit in vitro human B cells proliferation, differentiation to 
antibody-secreting cells and chemotaxis (Corcione et al.,’06). However, other in vitro 
studies have shown that MSC could support the survival, proliferation and 
differentiation to antibody-secreting cells of B cells (Traggiai et al., ’08). Probably, 
these different results may, at least in part, be accounted by different experimental 
conditions. 
In addition to adaptive immune system, in the last years has been demonstrated that 
MSC exert immunomodulatory effect also on innate immune system. 
Dendritic cells are the most potent APC and play a critical role in the initiation of 
primary immune responses. BM-MSC have been shown to inhibit the initial 
differentiation of monocytes into CD1a+ DC and in case of mature DC, MSC were able 
to down-regulate the expression of co-stimulatory molecules CD80 and CD86 and 
decrease IL-12 secretion, thus impairing the antigen-presenting function of the DC. 
These data suggest that MSC might modulate the immune system, not only acting 
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directly on T cells, but also at the very first step of the immune response through the 
inhibition of DC (Jang et al.,’05). 
The effect of MSC on NK cell-mediated cytotoxicity is controversial and related to 
different experimental approach. Few studies have demonstrated that the proliferation 
of IL-2 or IL-5 driven NK cells was inhibited by BM-MSC (Spaggiari et al., ’06). But, 
consistent with the low level of surface expression of MHC-I, MSC were highly 
susceptible to NK-cell-mediated cytotoxicity and the incubation of MSC with IFNγ, 
which up-regulate the expression of MHC-I, partially protected them from NK-cell-
mediated cytotoxicity. Finally, the interplay between MSC and NK cells in strictly 
related to microenvironment.  
As regards the interactions between MSC and neutrophils, another important cell type 
of innate immunity, BM-MSC have been shown to dampen the respiratory burst and to 
delay the spontaneous apoptosis of resting and activated neutrophils through an Il-6-
dependent mechanism (Figure 7) (Raffaghello et al., ’08). 
As regards the possible mechanisms of MSC-mediated immune modulation, several 
aspects have been evaluated. Soluble factors secreted by MSC, or by immune cells in 
response to MSC, and contact-dependent mechanisms has been proposed to collaborate 
for the MSC-mediated immune regulation. The interaction between MSC and their 
target cells involves cell-cell contact mediated by adhesion molecules as observed in 
several in-vitro studies. Moreover, soluble factors such as hepatocyte growth factor, 
prostaglandin E2, TGF-β1, indoleamine 2,3 dioxygenase (IDO), nitric oxide and IL-10 
have been involved, while other factors remain unknown (Rasmusson et al.,’04; 
Aggarwal et al.,’05; Krampera et al.,’06). 
 
The use of stem cells for tissue repair requires that cells can easily access to target 
organ, in this case the CNS, to exert their therapeutic effect. Several works have 
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demonstrated that MSC have the ability to home into damage brain migrating from the 
blood toward inflamed tissues where they had a protective effect (Vellieres ’03; Chen 
’03; Phinney ’05; Mahmood ’06; Ruster ’06). Transplantation experiments have shown 
that MSC distribute to a wide variety of tissues following systemic administration and 
may be capable of participating in ongoing cellular turnover and  replacement within an 
engrafted organ (Devine et al.,’03). Systemically administered MSC seem to 
preferentially home to the site of injury, where they support functional recovery. 
There is much evidence to support the theory that MSC can home to injured or 
inflamed tissue involving migration across endothelial cell layers. The mechanism by 
which MSC can migrate and extravasate from the blood vessels is probably due to the 
expression by injured tissue of specific receptors or ligands to facilitate trafficking, 
adhesion and infiltration of MSC, as in the case of recruitment of leukocytes. 
Chemokine receptors and their chemokine ligands are essential components involved in 
the migration of immune cells into sites of inflammation, and it has been recently 
demonstrated that MSC also express some of these molecules. MSC show coordinated 
rolling and adhesion behaviour on endothelial cells through a p-selectin and VCAM1-
dependent mechanism (Ruster et al.,’06; Chamberlain et al.,’07). In addition, MSC 
formed close contacts to the endothelial cells and were also able to integrate into the 
endothelial layer. Finally, they were able to leave the intact endothelium and finish their 
transmigration (Schmidt et al.,’06), thus showing that the systemic delivery of MSC 
could be a useful means to administer these cells in the clinic. 
After the engraftment into damaged tissue, it has been proposed that MSC could 
support tissue repair through multiple mechanisms, as inhibition of scar formation, 
decrease apoptosis, promotion of angiogenesis, and stimulation of intrinsic cells to 
support the re-establishment of the complex neurological pathways (Chen et al.,’03; 
Caplan et al.,’06).  
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MSC may have anti-inflammatory and anti-proliferative effects on microglial cells and 
astrocytes, resulting in the induction of a neuroprotective microenvironment (Li et 
al.,’05; Lanza et al.,’09). In addition, the implantation of MSC could stimulate 
proliferation, migration, and differentiation of the endogenous precursors that survived 
as more differentiated cells. This effect is mediated by the release of trophic molecules 
like nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), ciliary 
neurotrophic factor (CNTF), vascular endothelial growth factor (VEGF), fibroblast 
growth factor 2 (FGF-2) and the polycomb family transcriptional repressor (BMI-1) 
(Munoz et al., ’05; Zhang et al.’05; Rivera et al.,’06). 
It has also been proposed that MSC could support tissue regeneration by direct trans-
differentiation into cells of mesenchymal and non-mesenchymal lineages: several 
studies have demonstrated that MSC can also differentiate, under appropriate 
conditions, to form cells of various tissue lineages, including neurons (Brazelton et 
al.,’00; Mezey et al.,’00; Woodbury et al.,’00). In this regard, a large body of evidence 
has established the neural differentiation potential of MSC derived from BM. The 
treatment of BM-MSC with different molecules and growth factors induced very rapid 
morphological changes that are typical of neural cells together with the expression of 
neural markers, such as nestin, neurofilaments, MAP-2, or Neu-N (Winslet-Gendebien 
et al.,’05; Krampera et al.,’07). In addition, the data about the neuronal differentiation 
of A-MSC in terms of electrophysiological properties have provided not convincing 
results (Hung et al.’02): the use of chemical differentiation protocols, which promoted 
neural changes, could not support the acquisition of neuron-like excitability, which has 
been observed after co-culture with mature neural cells or transplantation into the brain 
(Wenisch et al.,’06). 
All these features make MSC a suitable candidate for cellular transplantation in the 
regenerative treatment of a variety of diseases. Much attention has been paid to MSC-
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based therapies for the treatment of autoimmune disease characterized by widespread 
degeneration and inflammation, like multiple sclerosis. 
Previous studies have shown that BM-MSC were effective in ameliorating both chronic 
and relapsing-remitting EAE. In these studies, BM-MSC were injected before the onset 
of disease or on the day of clinical symptom onset and the main mechanism was related 
to the immune-suppression on autoreactive B and T cells, and large amounts of MSC 
have been detected in lymphoid organs where T-cell priming occurs. As regards their 
effects within the inflamed CNS, this is still a matter of debate and the mechanisms of 
BM-MSC contribution to neuro-regeneration in chronic EAE are not clearly 
understood. In fact, murine BM-MSC do not express α4 integrins, and the study of BM-
MSC homing in EAE lesions has provided conflicting results regarding the capacity of 
BM-MSC to migrate into the inflamed CNS (Zhang et al.,’05; Zappia et al.,’05; 
Gerdoni et al.,’07; Kassis et al.,’08).  
More recently, human BM-MSC have been shown to be effective on chronic EAE, by 
inducing Th2-polarized immune response, reducing IFN-γ and Th17 producing cells 
and promoting oligodendrogenesis and inhibiting astrogliosis in EAE (Bai et al.,’09). 
Interestingly, recent data show that BM-MSC inhibit key mechanisms responsible for 
EAE induction by a paracrine conversion of CCL2 chemokine from agonist to 
antagonist of the Th17 cell function (Rafaei et al.,’09). Although BM has been the main 
source for the isolation of multipotent MSC, the harvest of BM is a highly invasive 
procedure and the number, differentiation potential, and the maximal life span of MSC 
from BM decline with increasing age. Therefore alternative sources to isolate MSC are 
subject to intensive investigations.  
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Adipose Stem Cells 
In the last years, much attention has been paid to adipose-derived mesenchymal stem 
cells (ASC) because adipose tissue is an abundant and appealing source of donor tissue. 
The adipose tissue is a highly complex tissue and consists of mature adipocytes, 
preadipocytes, fibroblasts, vascular smooth muscle cells, endothelial cells, resident 
monocytes/macrophages, and lymphocytes. The stromal-vascular cell fraction (SVF) of 
the adipose tissue has come more and more into the focus of stem cell research, since 
this tissue compartment provides a rich source of pluripotent adipose tissue-derived 
stem cells.  
 
                      
                                                   Figure 8: Adipose tissue 
ASC were firstly identified by Zuk and co-workers in 2001, who isolated a population 
of stem cells, termed processed lipoaspirate cells (PLA), from human lipoaspirates. 
They characterized phenotype, heterogenicity and growth kinetics of PLA and found 
that PLA were capable of multiple mesodermal lineage differentiation, as shown by the 
expression of several lineage-specific genes and proteins, and in addition could also be 
induced to express markers consistent with a neurogenic phenotype, suggesting an 
ectodermal potential (Zuk et al.,’01-’02).                      
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The simple surgical procedure, donor tissue is isolated under local anesthesia with a 
minimum of patient discomfort, the easy and repeatable access to the subcutaneous 
adipose tissue and the uncomplicated enzyme-based isolation procedures make this 
tissue source for MSC most attractive. Furthermore, cultured ASC seem to display an 
increased in vitro proliferative potential compared with BM-MSC, and could generate a 
clinically effective cell dose more rapidly than the same number of marrow cells: 1g of 
adipose tisse yields approximately 5x103 stem cells, which is 500-fold grater than the 
number of stem cells isolated in 1 g of bone marrow (De Ugarte et al, 2003; Fraser et 
al, 2004; Mitchell et al.,’06). In addition, ASC can be obtained in large quantities due to 
the quick proliferation kinetics and slow senescence ratio in vitro (Lin et al.,’08). 
Therefore, ASC do represent an alternative source of autologous adult stem cells that 
can be obtained repeatedly in large quantities.  
Most importantly, a comparative analysis of MSC obtained from bone marrow and 
adipose tissue clearly showed that ASC were not different regarding morphology, 
immune phenotype, success rate of isolating MSC, colony frequency, and 
differentiation capacity (Kern et al.,’06; Schaffler et  al.,’07). 
As regards the cell surface marker expression, a detailed analysis showed that ASC, 
like BM-MSC, expressed CD13, CD29, CD44, CD58,CD90, CD105, CD73 and Stro-1 
and were negative for endothelial and hematopoietic markers. However, certain key 
differences in surface marker expression between marrow and adipose tissue-derived 
cells were also detected. Interestingly, each of these differences was in the expression 
of adhesion molecules with known function in homing and mobilization of 
hematopoietic stem cells. Thus, ASC expressed CD49d (α4 integrin) which forms an 
heterodimer with CD29 to create very late activation antigen-4 (VLA-4) while cells 
derived from bone marrow did not. Unlike BM-MSC, very low expression of CD106 
(VCAM-I) was observed in ASC samples. Expression of CD106 in BM-MSC is 
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functionally associated with hematopoiesis and the low level of CD106 on ASC is 
consistent with the localization of these cells to a non-hematopoietic tissue (Zuk et 
al.,’02; DeUgarte et al.,’03). 
In addition to phenotype, also immunomodulatory properties of ASC are similar to 
BM-MSC. In this respect, several studied have demonstrated that ASC did not generate 
in vitro proliferation of allogeneic T cells and suppressed the lymphocyte proliferative 
response to mitogens and alloantigens in a dose-dependent manner. This inhibition 
persisted when ASC were separated from lymphocytes by a permeable membrane thus 
suggesting the involvement of soluble factors in addition to cell-cell contact 
mechanisms. Moreover, has been observed an inhibition of the production of 
inflammatory cytokines (TNFα, IFNγ, and IL-12) of T cells stimulated by nonspecific 
mitogenic and by allogeneic stimuli (Puissant et al.,’04; Yanez et al.,’06; McIntosh et 
al.,’06). 
Another feature required for the use of ASC in cellular therapy is the ability to migrate 
and access to damaged tissue. It has been demonstrated that ASC, after intravenous, 
intra-peritoneal or sub-cutaneous infusion,  were able to migrate to a wide range of 
tissues, including lungs, lymphoid organs, CNS and liver, and persist up to 75 days. No 
evidence of clonal expansion has been identified within any organ examined 
(Meyerrose et al.,’07). 
Similar to other stem cells population, ASC have shown to differentiate not only into 
osteoblasts, adipocytes and chondrocytes, but also, ASC can be induced to differentiate 
into endodermic and neuroectodermic lineages.  
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                Table 1: ASC transdifferentiation media (Schaffler et al.,’07) 
 
In this regard, several groups have demonstrated that under exposure to particular 
chemical medium, ASC could be induced to differentiate into specific cell lineages, 
such as neurons, endocrine pancreatic cells, hepatocytes, endothelial cells, and 
cardiomyocytes, thus showing a trans-differentiation potential (Woodbury ’02; Safford 
et al.,’04; Schaffler ’07). 
                
                         
                                      Figure 9: Trans-differentiation potential of ASC 
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As far as neural trans-differentiation is concerned, several studies have shown that 
using a complex neurogenic differentiation protocol with retinoic acid and BDNF, both 
murine and human ASC develop a neuronal morphology and immunocytochemical 
profile of neuronal cells, including the expression of TH and GABA-A. 
Electrophysiological properties are also suggestive of initial neuronal differentiation: 
differentiated ASC displayed resting membrane potential close to –60 mV, delayed-
rectifier type K+ currents, as well as voltage-dependent Na+ currents absent in basal 
conditions; however, these electrophysiological properties were not enough to fire an 
action potential (Krampera et al.,’07; Anghileri et al.,’08). However, this trans-
differentiation potential may be relevant for neuroregeneration. 
Based on these features, the abundant and practical donor tissue, immunophenotype, 
immunomodulatory properties and trans-differentiation potential, ASC represent an 
highly promising tool for cell therapy and tissue engineering. 
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AIM OF THE STUDY 
 
Multiple sclerosis and its animal model, EAE, are autoimmune disorders targeting the 
CNS, where the inflammatory response leads to demyelination and axonal 
degeneration. Chronic EAE is a suitable model to test therapeutic approaches which 
target simultaneously both inflammation and neuro-degeneration. MSC represent a 
promising therapeutic approach for neurological autoimmune diseases because they can 
differentiate in vitro into multiple mesenchymal and non-mesenchymal lineages and 
can efficiently induce the proliferation, migration and differentiation of neural 
endogenous progenitors through the secretion of neural growth factors, thus 
representing an attractive therapy for regenerative medicine (Munoz et al.,’05). In 
addition, MSC have relevant immune modulatory effects both in vivo and in vitro, as 
they can suppress many functions of immune cells (Uccelli et al.,’08). 
Among MSC, ASC represent a very attractive tool due to the abundant and easily 
accessible donor tissue. Moreover, ASC display multi-lineage plasticity in vivo an in 
vitro, have a much higher frequency in the adipose tissue than in the bone marrow and 
exerted immunomodulatory activity comparable to BM-MSC (Puissant et al.,05). In 
addition, a subpopulation of ASC expressed VLA-4 that plays a key role in the 
migration of cells into the inflamed CNS in EAE/MS (Pluchino et al.,’03). Finally, 
several groups including ours have found evidence for neural trans-differentiation of 
ASC in vitro (Anghileri et al.,’08), a property which may be relevant for 
neuroregeneration. 
On the basis of these considerations, we decided to investigate the efficacy of ASC in 
chronic EAE with a preventive and a more interesting therapeutic treatment protocol, 
focusing the attention on clinical and histological effects, homing and persistence of 
ACS into CNS as well as the molecular mechanisms mediated by injected cells.
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MATERIALS AND METHODS 
 
EAE induction and treatment protocols 
Chronic EAE was induced in 6-8 weeks old C57Bl/6 female mice purchased from 
Harlan Italy (S. Pietro di Natisone, Italy), by subcutaneous immunization with 200 µg 
of MOG35-55 peptide in incomplete Freud’s adjuvant containing 0.8 mg/ml 
Mycobacterium Tuberculosis, as previously described (Constantin et al., 1999). 
Pertussis Toxin (50ng; Sigma Aldrich, Milan, Italy) was injected at the day of 
immunization and after 48 hours. Body weight and clinical scores were daily registered 
according to a standard 0-5 scale: 0 = healthy, 1 = limp tail, 2 = ataxia and/or paresis of 
hindlimbs, 3 = paraplegia, 4 = paraplegia with forelimb weakness or paralysis, 5 = 
moribund or death animal (Figure 10). All animals were housed in pathogen-free 
conditions. The experiments received authorization from the Italian Ministry of Health, 
and were conducted following the principles of the NIH Guide for the Use and Care of 
Laboratory Animals, and the European Community Council (86/609/EEC) directive.                             
                                                  
 
                                Figure 10: EAE clinical and histological evaluation 
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Mice developed the first clinical signs of EAE at 12.7 ± 1.3 days post immunization 
(dpi), reached a peak at 14.0 ± 1.2 dpi and then presented a stable disease course, 
typical of this chronic model. EAE is characterized by extensive perivascular 
inflammation mainly represented by CD4+ and CD8+ T lymphocytes and macrophages 
within the spinal cord and less consistently in the brain. Inflammatory events are 
associated with widespread demyelination and progressive axonal loss (Figure 8) .  
To evaluate the clinical and pathological efficacy of ASC in chronic EAE, cells were 
administered with two distinct protocols: preventive and therapeutic. In the preventive 
set of experiments, ASC (either from wild type mice or from animals transgenic for the 
GFP fluorescent protein) were injected intravenously (iv) at 3 and 8 days post-
immunization (dpi), i. e. before the disease onset. In the therapeutic protocol, ASC were 
administered iv after the peak of disease severity, when the clinical score was stable (23 
and 28 dpi). For each injection, 1x106 MSC were resuspended in 1 ml of PBS without 
Ca2+ and Mg2+ and injected through the tail vein; each iv administration was divided in 
two injections of 0.5X106 ASC in 0.5ml vehicle. Control mice received only vehicle. 
 
Mesenchymal stem cell cultures 
Murine ASC were obtained from 6-8 weeks old C57Bl/6J mice, as well as from 
C57Bl/6-Tg(UBC-GFP)30Scha/J mice expressing the GFP fluorescent protein. The 
isolation of stromal-vascular fraction from adipose tissue was carried out on 10 ml of 
lipoaspirates, as previously described (Anghileri et al., 2008). Briefly, after washing in 
HBSS, extracellular matrix was digested at 37°C with collagenase A (Sigma), 
centrifuged at 1200g and the pellet was resuspended in NH4Cl; the stromal fraction was 
then collected by centrifugation and filtration. Murine BM-MSC were collected by 
flushing femurs and tibias with medium and filtered as previously described (Krampera 
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et al., 2003; Krampera et al., 2007). Cells were then cultured in DMEM, glucose, 
GLUTAMAX ITM, 15% heat-inactivated adult bovine serum (Celbio), penicillin and 
streptomycin (Invitrogen Corp. Carlsbad, CA). After 72 hrs, non-adherent cells were 
removed. When 70-80% adherent cells were confluent, they were trypsinized, harvested 
and expanded by using culture medium with 50ng/ml HB-EGF (R&D System, 
Minneapolis, MN). All the experiments were performed using MSC at 17-23 passages. 
 
MSC immunophenotyping and adhesion molecules expression 
Murine MSC were recognized by immunophenotype using mAbs specific for CD106 
(VCAM-1), CD9, CD44, CD80, CD138 and Sca1. In addition, the absence of 
haematopoietic markers (CD45, CD11c and CD34) and endothelial markers (CD31) 
was assessed as previously described (Krampera et al., 2003). All mAbs were 
purchased from Pharmigen/Becton Dickinson (Palo Alto, CA, USA). For the study of 
adhesion molecule expression, ASC were labelled with fluorescent antibodies for α4 
integrins  (PS/2 clone, kindly provided by Dr. Eugene Butcher, Stanford University), 
LFA-1 (anti-aL-chain; clone TIB213 from American Type Culture Collection/ATCC, 
VA, USA), PSGL-1 (clone 4RA10, kindly provided by Dr. Dietmar Vestweber, Max 
Plank Institute, Germany), L-selectin (Mel-14 clone, ATCC) and CD44 (IM/7 clone, 
ATCC). Isotype-matched antibodies were used as controls. For immunophenotypic 
analysis and adhesion molecule expression, MSC were detached using trypsin/EDTA 
(Sigma), washed and resuspended at 106 cells/ml. Cell suspension was incubated with 
15% adult bovine serum, followed by incubation with the specific mAbs at 4°C for 30 
minutes. At least 10,000 events were analyzed by flow cytometry (FACScalibur, 
Becton Dickinson) using the Cell Quest software. 
 
 35 
ImageStream data acquisition and analysis  
ASC were prepared for immunostaining as described above and then incubated with 10 
g/ml of  anti-α4 integrins mAb for 30 min on ice. After washing, cells were stained 
with goat anti-rat IgG-PE conjugated (Caltag Laboratories). Stained cells were re-
suspended in PBS and images were acquired on the ImageStream® imaging cytometer 
System 100 (Amnis Corporation, Seattle, WA, USA). Images of fixed cells were 
collected and analyzed using ImageSteam Data Exploration and Analysis Software 
(IDEAS) (George et al., 2006). α4 integrin clustering was evaluated analyzing the 
distribution on the cells surface of the fluorescence pattern. Uniform (uniform 
distribution of fluorescence), Clustered (small spots of fluorescence) and Caps (big 
clusters of fluorescence) cells were gated using the Area feature Vs the Delta Centroid 
XY feature (Bolomini-Vittori et al., 2009). The area feature was calculated for channel 
4 (PE-specific emission; area of fluorescence), applying to the images a Threshold 
mask, previously created; this feature allowed us to discriminate between cells with 
larger fluorescence area (high area values) and smaller fluorescence area. The Delta 
Centroid (DC) XY feature calculates the distance between the center of the PE 
fluorescence image and the center of the brightfield image for each image pair. This 
feature distinguished images with globally distributed staining (lower DC values) from 
those with capped staining (higher DC values). When plotted versus the Area feature, 
DC XY permits to distinguish between punctate and uniform staining at the same time 
(Bolomini-Vittori et al., 2009). In our analysis, cells with Area values higher than 600 
and Radial Delta Centroid values lower than 16 were considered “Uniform” cells for 
their fluorescence distribution. Cells with Area values lower than 600 and Radial Delta 
Centroid values lower than 16 were considered “Clustered” cells (small spots of 
fluorescence). Cells with Radial Delta Centroid values higher than 16 were considered 
“Caps” cells (highly polarized fluorescence). 
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Proliferation assays 
MOG35-55 activated T cells were obtained from draining lymph nodes of mice 
immunized with antigen as previously described (Constantin et al., 1999). CD4+ T cells 
(2x105/well) were co-cultured with 5,000, 2,000 and 1,000 irradiated ASC in 96-well 
microtiter plates in the presence of 30 mg/ml antigen peptide and 8x105 APC (irradiated 
splenocytes) for 3 days. [3H] thymidine (1mCi) was added in each well 18h before the 
end of cultures. [3H] thymidine uptake was determined in a Microplate Scintillation 
Counter and expressed as counts per minute (CPM). In separate experiments we studied 
the ex vivo proliferation of T cells from peripheral lymph node cells isolated from mice 
immunized with MOG35-55 peptide and treated or not with ASC. Total draining lymph 
node cells were isolated 7 days after disease onset from mice treated with ASC in the 
pre-clinical phase of disease (3 and 8 dpi). Total draining lymph node cells were 
isolated at the end of the experiment (72 dpi) in mice receiving ASC after disease 
stabilization (at 23 and 28 dpi). For all ex-vivo proliferation experiments, 1x106 
cells/well were cultured in 96-well microtiter plates in the presence of 10-30 µg/ml 
MOG peptide or 1 µg/ml anti-CD3 plus 2 µg/well anti-CD28mAb. After 72 hrs of 
incubation, cultures were pulsed for 18 hrs with 1 µCi per well of [H3]-thymidine, and 
proliferation was measured from triplicate cultures.  
 
ELISA and Bio-Plex assays  
Supernatants from lymph node cells isolated from mice treated with ASC in the pre-
clinical phase of disease or after disease stabilization, or derived from in vitro co-
cultures between MOG35-55 activated T cells and ASC were used for Bioplex cytokine 
assays (BioRad), following manufacturer’s instructions. Briefly, anti-cytokine 
conjugated beads were plated in 96-well microtiter plates and then removed by vacuum 
filtration. Samples were then added in each well, and the plate was incubated for 30 
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min by mixing at 300 rpm. Bio-Plex cytokine assays were then washed and the 
detection antibody was added to each well for 30 min. After washing, streptavidin-PE 
was added and samples were then analyzed immediately by a Bioplex array-system. 
Unknown cytokine concentrations were automatically calculated by Bio-Plex software 
using a standard curve derived from a recombinant cytokine standard. To determine the 
production by ASC of bFGF, BDNF, CNTF, PDGF-AB, VEGF and IGF-I, 
supernatants were obtained from ASC (1x105) in basal condition and/or after incubation 
with TNFα (50U/ml) for 24 hrs and analyzed by Quantikine® ELISA Immunoassay 
(R&D), following the manufacturer’s instructions. Briefly, cells were grown in 24-well 
plates and the supernatants were harvested and centrifuged for 10 min to remove cell 
debris. Samples were added in 96-well pre-coated plates and incubated for 2 hrs at RT. 
After washing, a specific polyclonal antibody followed by substrate solution were 
added and the colour development was measured at 450nm (BioRad Microplate 
Reader). The concentration of growth factors was calculated using the standard curve. 
 
Cell transfection and biolumiscence in vivo imaging 
Murine ASC were transiently transfected with a plasmid encoding for the firefly 
luciferase (Photinus pyralis), under the control of the SV40 early enhancer/promoter 
region (pGL4.13 internal control vector; Promega Corporation, USA). Transfection was 
performed by lipofection with the LipofectamineTM 2000 reagent system (Invitrogen), 
according with the manufacture’s instructions; cells were transfected in a 12 well plate 
(600,000 cells/well) and the Lipofectamine (l)/DNA (g) ratio used was 2.5/1. After 
lipofection, cells were washed and kept for 18 h at 37°C in complete medium. The 
transfection efficiency was evaluated transfecting with the same protocol ASC with a 
plasmid encoding for eGFP, under the control of a CMV promoter (pEGFP-N1 vector; 
Clontech). Cells were analyzed by flow cytometry for the eGFP fluorescence: 
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efficiency was always higher than 55% in all the experiments. The day after 
transfection, 1.2 x106 ASC were transplanted iv into healthy or EAE mice (7 to 9 days 
after disease onset). For anti-4 integrin treatment, mice were injected iv with 500 g 
of anti-α4-integrin mAb every other day, whereas cells were incubated before 
transplantation with 100 g anti-α4 mAb in 200 l PBS, for 30 min on ice. 
Bioluminescent signal generated by luciferase activity was measured using the In Vivo 
Imaging System IVIS® 200 (Xenogen Corporation, USA). An aqueous solution of the 
luciferase substrate D-luciferin (150 mg/kg; Xenogen) was injected iv 12 min before 
imaging. Animals were under general anesthesia (2.5% isoflurane in oxygen). Images 
were acquired using a CCD camera and analyzed with the Living Image 2.6 software 
and the Living Image 3D (Xenogen). Acquisition time was of 6 min (binning factor: 8; 
field of view: 12,8; f/stop 1; open filter). A pseudo-color image representing light 
intensity (blue, least intense; red, most intense) was created for each mouse. 
 
Intravital microscopy  
ASC were labelled with green 5-chloromethylfluorescein diacetate (Molecular Probes, 
Eugene, OR). To mimic brain inflammation in early phase of EAE, C57Bl/6  female 
mice were injected i.p. with 12 µg of LPS (Escherichia coli 026:B6; Sigma-Aldrich) 5–
6 hrs before the intravital experiment (Piccio et al., 2002). Briefly, animals were 
anesthetized and the preparation was placed on an Olympus BX50WI microscope and a 
water immersion objective with long focal distance (Olympus Achroplan) was used. A 
total of 1x106 fluorescent labelled cells/condition was slowly injected into the carotid 
artery by a digital pump. The images were visualized by using a silicon-intensified 
target video camera (VE-1000 SIT; Dage MTI) and a Sony SSM-125CE monitor and 
recorded using a digital VCR (Panasonic NV-DV10000). ASC that remained stationary 
on venular wall for 30 s were considered adherent.  
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Histology and immunohistochemistry 
At sacrifice, samples of brain, lumbar, dorsal and cervical spinal cord were snap-frozen 
in isopentan immersed in liquid nitrogen and stored at -80°C until use. Fifteen µm-thick 
cryostat sections were serially obtained from spinal cord and brain samples and 
processed for H&E, Spielmeyer stainings and immunohistochemistry to evaluate the 
presence of inflammatory cells, demyelination, axonal loss and oligodendrocyte 
progenitors, according to standard protocols and as previously described (Lovato et al., 
2008; Lolli et al., 2005). Histological assessment of spinal cord demyelination 
(Spielmeyer) and inflammatory infiltrates (H&E) in lumbo-sacral segments was 
performed calculating affected areas in at least three sets (100 µm apart) of six sections 
for each animal. For immunohistochemistry, primary antibodies for 
macrophages/monocytes, CD3, CD4, CD8 T cells (Serotec, Oxford, UK), 
neurofilaments (MAB 5448; 1:1000; Chemicon, Temecula, CA) or PDGFαR (Sigma) 
were incubated overnight. After washing, anti-rat biotinylated secondary antibody was 
added; the reaction was visualized with ABC kit (Vector Laboratories, Burlingame, 
CA) and diaminobenzidine (Sigma). Images of immune-peroxidase were obtained with 
Zeiss Axiophot microscope and Axiocam camera with Axiovision software. Lesions 
were identified on digital images of Spielmeyer-stained or H&E sections; the lesion 
area was determined following a manual outline of the lesion border and expressed as 
percentage of the total spinal cord section area. For the determination of axonal loss, 
the number of neurofilament-reactive profiles was manually counted within the lesions 
(on sections adjacent to Spielmeyer-stained section) and their density was calculated by 
dividing the manual counts by the lesion area. The assessment of neural precursors was 
performed by counting the number of PDGFαR+ cells on eight random 40X fields in the 
entire spinal cord section. In order to evaluate the tissue distribution, the relationship 
with inflammation and the differentiation by GFP+ ASC in lymphoid organs and in 
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spinal cord, sections were incubated with DAPI and then with anti-CD3, GFAP (Dako), 
O4 (MAB345; 1:100; Chemicon) or PDGFαR mAbs overnight (Bonetti et al., 1997); 
the signal was then detected by appropriate secondary biotinylated antibodies and 
Streptavidin Texas Red (Vector). Slides were viewed under a Zeiss MC80 microscope 
or Leica TCS SP5 tandem confocal scanner with acquisition of images at different 
wave-length (DAPI 455nm, GFP 509nm, Texas Red 615nm). The proportion of GFP+ 
MSC undergoing neural differentiation was calculated by dividing the number of GFP+ 
MSC expressing neural phenotypic markers by the total number of GFP+ MSC in lesion 
areas. All the above counts were performed in three sets (four sections 100 µm apart) 
for each animal. All data are expressed as mean percentage ± SD.  
 
Statistical analysis 
Statistical analysis using a two-tailed Student’s t-test was performed to evaluate 
differences between A-MSC-treated and control conditions for several parameters: T 
cell proliferation, cytokine production, pathological alterations and number of 
oligodendrocyte progenitors in EAE lesions.  
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RESULTS 
 
Preventive administration of A-MSC reduces the severity of chronic EAE 
 
Clinical and neuropathological effects of A-MSC-based therapy 
The preventive administration of ASC significantly ameliorated the subsequent clinical 
course of EAE. The mean clinical score at  disease peak was significantly lower in ASC 
injected mice compared to controls (mean ± SD: 1.1 ± 0.7; vs  2.5 ± 0.7 in control 
mice; p<0.002)  and also daily clinical score were significantly lower in treated mice 
compared to controls starting from 13 dpi until sacrifice (Figure 11 and Table 2). 
                        
                                Figure 11: Preventive protocol EAE - clinical course 
 
Table 2: Clinical and pathological features of EAE – preventive protocol             
Treatment      
(n. animals) 
Disease     
Onset          
(dpi) 
Mean   
Maximum 
Score        
Mean    
Cumulative          
Score       
Inflammatory 
Area   (%)           
Demyelinated 
Area (%)          
Axonal 
Loss  (%)           
 Controls 
(10) 
12.7±1.3           2.5±0.7              77.9±36.2    18.9±9.5             17.7±8.5          21.8±4.0             
 ASC (10) 13.7±2.1              1.1±0.7*                32.8±21.7*   8.1±7.7**               9.1±7.6**             9.2±5.1**               
 
 *p<0.002; **p<0.0005; 
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The pathological analysis at 50 dpi of spinal cord sections in all control mice showed 
the presence of demyelinated areas and inflammatory infiltrates, composed of T 
lymphocytes and monocyte/macrophages (Figure 12), while, mice injected with ASC 
showed a significant reduction of the areas of inflammation, demyelination and axonal 
loss (Table 2).  
 
                           
                Figure 12: Histological analysis of spinal cord – preventive protocol   
 
Hematoxylin and eosin (Figure 12 A, B) and Spielmeyer (Figure 12 C, D) stainings of 
lumbar spinal cords showed reduction of inflammation and demyelination in ASC-
treated mice, as compared to control mice. Immunohistochemistry for CD3 T 
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lymphocytes (Figure 12 E, F) and macrophages (Figure 12 G, H) on serial sections 
showed decreased number of inflammatory cells in EAE lesions from ASC-treated 
mice in comparison to controls. 
The composition of inflammatory infiltrates, as well as the apoptotic rate of 
perivascular cells, were similar in both groups. GFP+ ASC had similar clinical and 
pathological effects on EAE as compared to wild type ASC, suggesting that fluorescent 
ASC are suitable for mechanistic studies in vivo. No anti-GFP autoreactivity was 
detected in the serum from ASC treated EAE animals by performing 
immunocytochemistry on GFP+ ASC cultures. In addition, no evidence of GFP 
reactivity was seen in CD11b+ macrophages in all EAE lesions examined with both 
treatment protocols. 
 
Mechanisms of the beneficial effects of the preventive treatment with A-MSC in 
EAE: Immune regulation 
Previous reports have shown a significant inhibition of proliferation of autoreactive 
immune cells by BM-MSC (Zappia et al, 2005). In agreement with these results, we 
found that ASC inhibited MOG-specific T lymphocyte proliferation both in vitro and in 
vivo. In fact, ASC co-cultured in vitro with CD4+ T cells in the presence of MOG35-55 
peptide exerted a dose-dependent inhibition of T cell proliferation (Figure 13) and 
induced a significant decrease of IFNγ (Figure 14 A), GM-CSF, IL-17, IL-4 and IL-5 
production (data not shown). No effect was observed on the production of TNF-α and 
IL-1β, which were produced in low amounts after stimulation in vitro with MOG (data 
not shown).  
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         Figure 13: Effect of ASC on the proliferation of autoreactive T cells in vitro. 
 
 
             A            B      
                      Figure 14: Effect of ASC on cytokine production in vitro.  
                                               
Interestingly, we observed a selective and significant increase of IL-10 production as 
compared to control condition (p<0.02), suggesting that ASC promote the generation of 
T lymphocytes with regulatory activity in vitro (Figure 14 B).  
We next asked whether the effects observed in vitro were also responsible for the in 
vivo activity of ASC. Ex vivo analysis of peripheral lymph node cells isolated from 
mice treated with ASC showed a significant reduction of proliferation in the presence 
of MOG35-55, when compared to control mice (Figure 15 A). In addition, the production 
of both pro-inflammatory and anti-inflammatory cytokines by peripheral lymph node 
cells isolated from mice treated with ASC and stimulated with MOG35-55 was generally 
suppressed in comparison with control EAE animals (Figure 15 B, C).  
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              Figure 15: Proliferation and cytokine production – preventive protocol 
 
ASC homing and local neurogenesis in EAE lesions  
GFP+ ASC distributed in normal mice mainly in the spleen and lymph nodes; by 
contrast, in EAE mice ASC displayed an increased migration to lymphoid organs but 
also penetrated into the spinal cord (Figure 16). The number of ASC gradually 
decreased in time in spleen and lymph nodes, while it persisted almost unchanged 
within the spinal cord up to 93 dpi. We next investigated the localization of ASC within 
the normal and inflamed spinal cord. In basal conditions, a very limited number of ASC 
was found in the sub-meningeal spaces of both brain and spinal cord (0,7 ± 0,3 
cells/mm2).  
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                           Figure 16: Distribution of ASC – preventive protocol 
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In spinal cord from mice with EAE the vast majority of ASC was detected mainly 
within the lesions, both associated with inflammatory cuffs and sparse in the white 
matter parenchyma. Confocal microscope image with DAPI (blue), CD3 (red) and GFP 
(green) showed the presence of GFP+ ASC in EAE spinal cord at 16 (Figure 17 A) and 
30 dpi (Figure 17 B); only few GFP+ ASC were observed either in regions of normal 
appearing white matter or in the gray matter. GFP+ ASC are detected in white matter 
spinal cord up to 93 dpi (Figure 17 C, D). 
 
           
            Figure 17: Distribution of ASC during the pre-clinical phase of EAE 
 
To explore the mechanisms sustaining the homing of ASC to inflamed CNS we 
evaluated their adhesion molecule profile. Flow cytometry studies were performed in 
order to characterize on ASC and BM-MSC the expression of adhesion molecule 
repertoire, namely anti-leukocyte function-associated antigen (LFA-1), α4 integrins, L-
selectin, P-selectin glycoprotein ligand (PSGL)-1, CD44. The results show up to 25% 
of ASC, but not BM-MSC, express α4 integrin, suggesting that a sub-population of 
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ASC might gain access to the inflamed brain (Gronthos et al.,’01; Rafei et al.,’09) 
(Figure 18).  
          
                   Figure 18: Adhesion molecule profile of BM-MSC and ASC. 
 
These results, together with previous data showing that MSC express β1 integrins, 
suggest that ASC express VLA-4 (α4β1) integrin. Moreover, ImageStream analysis 
revealed that the vast majority of VLA-4+ cells express activated VLA-4. ASC were 
stained with anti-α4 integrin antibody followed by anti-rat IgG-PE. Analysis of α4 
integrin clustering was evaluated by analyzing the distribution on the cells surface of 
the fluorescence: Uniform (uniform distribution of fluorescence), Clustered (small 
spots of fluorescence) and Caps (big clusters of fluorescence) (Figure 19 A).  
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                                                Figure 19: VLA-4 expression 
 
The quantification of the three different populations of ASC, according with α4 integrin 
clustering on their surface shows that 92% of ASC displayed functionally active α4 
integrin (Figure 19 B).          
To assess their ability to interact with inflamed brain endothelium, we performed 
intravital microscopy experiments in an experimental model in which brain 
endothelium expresses high levels of VCAM-1, the endothelial ligand for VLA-4 
integrin (Constantin et al.,’00; Piccio et al.,’02). We found that fluorescently labelled 
ASC arrested in inflamed brain venules in intravital microscopy experiments. Cells are 
the bright intravascular dots (arrows) inside blood vessels labelled with fluorescent 
dextrans (Figure 20). The results obtained confirmed that ASC were able to efficiently 
adhere to inflamed brain vessels in vivo.  
 49 
                                                  
                                              Figure 20: Intravital microscopy. 
 
To definitively demonstrate that ASC accumulate in the inflamed brain through a VLA-
4-dependent mechanism, we performed bioluminescence in vivo assay. ASC transfected 
with the luciferase reporter gene were transplanted iv in healthy or EAE mice (7 to 9 
days after disease onset).  
        
 
                       Figure 21: ASC migration into CNS of EAE mice. 
 
Bioluminescent signal by luciferase activity generated by transfected ASC in 
transplanted mice was visualized by the IVIS® 200 imaging system, 7 days after ASC 
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injection. Images show the bioluminescent signal detected in one representative animal 
per group ( Figure 21: left: healthy mouse; middle: EAE; right: EAE + anti-α4 integrin 
antibody). The colour scale next to the images indicates the signal intensity, with red 
and blue representing high and low signal intensity, respectively. The results showed 
that ASC accumulate preferentially in spleen and liver in healthy mice, whereas in EAE 
mice the bioluminescent signal is prevalent in areas corresponding to dorsal-lumbar 
spinal cord. Interestingly, the pretreatment with anti-α4 integrin antibody dramatically 
inhibited ASC accumulation in inflamed CNS (Figure 21).                    
 
The fate of ASC after iv injected was assessed by immunofluorescence in the spinal 
cord of healthy and EAE mice, by evaluating the number of GFP+ cells expressing the 
glial phenotypic markers GFAP for astrocytes, O4 for mature oligodendrocytes and 
PDGFα R for oligodendroglial precursors (Figure 22 A, B).   
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Figure 22: A: Confocal microscope image with DAPI (blue), PDGFαR (red) and 
GFP (green); B: quantification of glial markers expression upon ASC into the 
spinal cord.  
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We then assessed whether ASC could favour remyelination and regeneration when 
administered in the pre-clinical phase of disease. Given the relevance of the PDGF 
pathway in both oligodendrogenesis and MSC self-renewal (Lachapelle et al.,’02; 
Tokunaga et al.,’08), we investigated adhesion molecule profile of ASC and we first 
assessed by flow cytometry the expression of PDGFα R on ASC cultures: 28% of them 
displayed PDGFα R (Figure 18). We found that ASC treatment promoted local 
neurogenesis by inducing a three-fold increase of PDGFα R+ oligodendrocyte 
progenitors (15.0 ± 2.1), when compared to untreated mice (5.4 ± 1.1) (Figure 23 A, B). 
                
Figure 23: Increase of oligodendrocyte precursors, identified with anti PDGFαR, 
in ASC treated mice compared to controls. 
 
We then asked whether the increase in oligodendrocyte progenitors derived from local 
precursors or from PDGFα R+ ASC penetrated in the spinal cord. In this regard, the 
comparative analysis between the total number of PDGFα R+ cells and the number of 
GFP+/PDGFα R+ ASC showed that about 40% of oligodendrocyte precursors derived 
from ASC (Figures 16 and 22 B), a proportion similar to that found in culture. 
We next investigated whether GFP+ ASC migrated in the parenchyma underwent 
mature glial differentiation. As summarized in Figure 22 B, the double staining with 
glial phenotypic markers showed that a very limited subset of GFP+ ASC displayed 
mature glial differentiation markers (i. e. GFAP or O4) in EAE lesions. No evidence of 
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binucleated GFP+ cells expressing such markers was observed in all samples examined. 
Thus, these results suggest that ASC penetrated and persisted into inflamed spinal cord, 
where they contributed to activate oligodendroglial progenitors. To better support this 
point, we then assessed by ELISA assay the secretion by ASC of growth factors, which 
may influence their self-renewal as well as the process of oligodendrogenesis.  
                        
                             Figure 24: Secretion in the supernatant of growth factors by ASC 
 
As summarized in Figure 24, we found that ASC both in basal conditions and after 
TNF-α stimulation produced detectable amounts of bFGF, PDGF-AB and BDNF and 
considerable amounts of IGF-I and VEGF which have been shown to activate 
circulating and resident stem cells tissue and promote angiogenesis (Crisostomo et 
al.,’08); no production of CNTF was observed in any condition (data not shown). 
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Therapeutic administration of ASC ameliorates the severity of chronic EAE 
 
Clinical and neuropathological effects 
Since ASC are able to exert a beneficial effect in the preventive protocol, more 
interestingly and in contrast with the results obtained with BM-MSC (Zappia et al.,’05), 
we found that therapeutic administration of ASC at 23 and 28 dpi, when disease entered 
an established clinical course, significantly ameliorated the disease, thus displaying a 
true therapeutic effect. Daily mean of the clinical scores shows that after about two 
weeks ASC-treated animals displayed a significant amelioration of the clinical course 
in comparison to control EAE mice (Figure 25 and Table 3). The effect started to be 
clinically significant at 41 dpi and increased progressively until sacrifice at 72 dpi. The 
pathological analysis at sacrifice confirmed the beneficial effect of ASC, in terms of 
reduction of either demyelination, inflammation and axonal loss (Table 3).  
 
 
                          
                              Figure 25: Therapeutic protocol EAE- clinical course 
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         Table 3: clinical and pathological features of EAE – therapeutic protocol 
Treatment      
(n. animals) 
Mean   
Maximum 
Score        
Mean   
Maximum 
Score (0-28 
dpi)         
Mean    
Cumulative          
Score (29-72 
dpi)        
Inflammatory 
Area   (%)           
Demyelinated 
Area (%)          
Axonal 
Loss  (%)           
 Controls (10) 2.2±0.4           25.2±5.3              92.2±25.1     14.2±6.9             14.6±6.6          22.6±6.0             
 ASC (10) 2.3±0.4             24.8±6.5                63.0±29.6*    7.7±2.3*               7.1±3.1*             3.9±1.1**               
*p<0.002; **p<0.0005. 
 
Hematoxylin and eosin (Figure 26 A, B) and Spielmeyer (Figure 26 C, D) stainings of 
lumbar spinal cords confirmed that clinical amelioration was accompanied by 
significant reduction of both inflammation and demyelination in ASC-treated animals, 
in comparison to control mice. Strikingly, axonal density in spinal cord of ASC-treated 
animals was almost comparable to normal  healthy mice (Table 3).  
                   
              Figure 26: Histological analysis of spinal cord – therapeutic protocol   
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Mechanisms of the beneficial effects of the therapeutic treatment of EAE with ASC: 
Immune regulation 
The therapeutic effect of ASC on established EAE induced us to seek for their 
underlying mechanisms of action. Interestingly, homing of ASC into lymph nodes was 
lower in mice receiving cells after the disease onset, when compared to animals treated 
in the pre-clinical phase of disease. In fact, the number of ASC injected with the 
therapeutic protocol detected in lymph nodes was only two times higher than that 
observed in healthy mice and about five times lower than mice receiving ASC in the 
pre-clinical phase of disease (Figure 27).  
 
               
                    Figure 27: Quantification of GFP+ ASC in lymphoid organs. 
 
The proliferation of MOG-specific T cells isolated from mice injected in a chronic 
phase of EAE and the production of pro-inflammatory cytokines was not different from 
control mice at 72 dpi (Figure 28 A). 
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                         Figure 28: Cytokine production – therapeutic protocol 
 
However, cytokine contents in supernatants of lymph node cells showed that basal 
production of IFNγ was increased in cells obtained from mice treated with ASC (Figure 
28 B). Interestingly, we observed an enhanced production (p<0.02) of IL-4, IL-5 and 
IL-10 by T cells both in the absence and in the presence of antigen (Figure 28 C), 
suggesting that ASC injected in mice with established disease induced a shift towards a 
Th2 phenotype, contributing to disease amelioration.                              
 
ASC homing to CNS and induction of local neurogenesis in EAE lesions 
In addition to lymphoid organs, the analysis of the distribution of GFP+ ASC in spinal 
cord from EAE mice sacrificed at 72 dpi confirmed the ability of these cells to home 
into the inflamed CNS when injected in mice with established disease. In this regard, 
their distribution pattern and quantity (10.1 ± 2.2 GFP+ cells/mm2 in EAE lesions) were 
comparable to those observed with the preventive protocol (Figure 29).                                 
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                          Figure 29: Homing of ASC into spinal cord during EAE. 
 
We next sought for the mechanisms responsible for the therapeutic effect of ASC. We 
first evaluated the number of oligodendrocyte precursors, which may contribute to 
neuroregeneration. As observed in mice receiving ASC during the pre-clinical phase of 
EAE, ASC penetration in EAE lesions induced a three-fold increase of the total number 
of PDGFα R+ cells, when compared to EAE lesions from control mice (Figure 30 A).  
 
 
 
Figure 30: A: Increase of PDGFαR+ cells in ASC-treated mice; B: subset of GFP+ 
cells (green, B3) express PDGFαR (red B1), as evident in merge image (B and 
inset); nuclei are stained with DAPI (blue B2). 
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The comparative analysis of the total number of PDGFα R+ cells and of GFP+/PDGFα 
R+ ASC showed that about 20% of oligodendrocyte precursors derived from ASC (a 
proportion similar to that expressing PDGFαR on ASC before injection, Figure 18), 
whereas the majority originated from local precursors (Figure 30 B). 
As shown also for mice treated in the pre-clinical phase of disease, we observed that a 
very limited number of GFP+ cells expressed the markers of mature glial cells (i. e. 
GFAP or O4) (Figure 31 A); in particular, mature oligodendrocyte derived from ASC 
were less than 2%, suggesting that ASC do not significantly contribute directly to the 
process of remyelination. As in preventive protocol, no evidence of binucleated GFP+ 
cells expressing neural markers was observed in all samples examined. 
 
 
Figure 31: A: Differentiation of ASC injected during established EAE; B: 
examples of GFP+ cells (B2, C2) expressing the markers of O4+ mature 
oligodendrocytes (B3) or GFAP+ astrocytes (C3), as visible in merge images (B,C); 
DAPI staining in B1 and C1. 
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DISCUSSION 
 
The rapid scientific progress in the last years in stem cell biology has generated growing 
enthusiasm for the development of therapeutic strategies in the field of regenerative 
medicine and tissue regeneration will be a major challenge for degenerative diseases and 
even for the amelioration of normal ageing. As outlined in the Introduction, stem cells 
can be obtained from various sources, including embryos, foetal tissues, umbilical cord 
blood and adult organs. Once isolated, these cells may be easily induced to expand and 
differentiate into functional progenies suitable for cell replacement. Stem cells-based 
therapies could be used to cure degenerative disorders such as hematologic, 
cardiovascular, muscular, gastrointestinal pathologies, chronic hepatopathies, and 
neurological diseases (Boucherie et al.,’09).  
Stem cells represent a promising approach in the treatment of neurological disorders and, 
in particular, for autoimmune diseases of the CNS. Multiple sclerosis is the most frequent 
inflammatory CNS pathology, which is sustained by anti-myelin autoreactive cells; in 
addition to inflammatory-mediated demyelination, a distinctive feature of this disease is 
the concomitant presence of axonal/neuronal damage, which strictly correlates with 
irreversible neurological deficits that eventually leads to important limitation to MS 
patients. These features explain the challenge that MS represents for many scientists 
working with stem cells; for these reasons, MS is the prototypic disease where to test 
therapeutic tools that couple neuro-regeneration and immune modulation. Among adult 
stem cells, NSC probably represent the gold standard in neurological disorders, because 
of their capacity to generate a progeny of differentiated functional daughter neural cells 
and their ability to penetrate into the CNS, where they display also potent anti-
inflammatory effects. These features made NSC an attractive cell source for the treatment 
of autoimmune neurological diseases characterized by widespread inflammation, 
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demyelination and axonal loss like MS and its animal model (Pluchino et al.,’03, ‘05). 
However, the source and the availability of stem cells is becoming a crucial issue for their 
clinical application and the invasiveness associated with isolation of NSC may limit their 
use in human applications. In this regard, BM-MSC have been considered an elective 
source of adult stem cells. In addition to self renewal potential, BM-MSC couple an 
immunomodulatory activity with the ability to penetrate into damaged tissue, where they 
could release trophic factors or undergo trans-differentiation resulting in directly 
regenerative effect (Chamberlain et al.,’07). 
In consideration of these features, several groups have tested the efficacy of BM-MSC in 
the treatment of autoimmune neurodegenerative disorders; in particular, BM-MSC have 
been shown to ameliorate both chronic and relapsing-remitting EAE, reducing 
inflammatory infiltrates, demyelinated areas and axonal loss (Zappia et al.,’05; Zhang et 
al.,’05; Gerdoni et al.,’07). However, the beneficial effect in chronic EAE was evident 
only when murine BM-MSC were injected before the disease onset (Zappia et al.,’05). In 
both chronic and relapsing EAE, the main mechanism was related to the immune-
suppression exerted by murine BM-MSC on autoreactive B and T cells (Puissant et 
al.,’05; McIntosh et al.,’06; Gerdoni et al.,’07), while their effects within the inflamed 
CNS are still a matter of debate. In this regard, it has been demonstrated that murine and 
human BM-MSC showed different homing into CNS, related to distinct panels of 
adhesion molecules expressed. The lack of VLA-4 on murine BM-MSC prevented 
migration through BBB which can exert their biological effects only in peripheral target. 
On the other hand, it has been shown that human VLA-4+ BM-MSC (Brooke et al.,’08) 
could exert, in addition to immunomodulation, a direct neuroregenerative effect due to 
the capacity to migrate into the CNS (Zhang et al.,’04). In line with this evidence, human 
BM-MSC have been recently shown to be effective on chronic EAE: clinical 
improvement was accompanied by changes in glial cell responses with increased 
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oligodendrocytes and decreased astrocytes in lesion areas as well as changes in spleen-
cell responses. In addition, in animals that received BM-MSC, there was a significant 
reduction in pro-inflammatory cytokines including IL-17, IFN-γ and TNF-α and a 
significant increase in anti-inflammatory cytokines including IL-4 and IL-5, thus BM-
MSC could regulate the balance of T lymphocytes between Th1/Th17 to Th2-polarized 
immune response and modify the cytokines released during EAE (Bai et al.,’09). 
Interestingly, recent data show that BM-MSC specifically inhibit key mechanisms 
responsible for EAE induction by a paracrine conversion of CCL2 chemokine from 
agonist to antagonist of the Th17 cell activation and migration (Rafei et al.,’09).  
However, although promising results have been obtained with BM-MSC in the 
experimental model of MS, several aspects dampen the initial enthusiasm for their 
application in humans. First of all, the lack of therapeutic effect exerted in EAE when 
murine BM-MSC are injected after the onset of disease. Translating the results obtained 
in EAE to MS patients, we should expect a good preventive effect on relapsing MS by 
BM-MSC, but little or no expectation once the patient enters the progressive phase. 
These limitations will greatly reduce the impact of stem cell-based therapy in MS, since 
the same effects can be nowadays obtained by a number of immune modulating or 
immune suppressive compounds. In addition, the invasive nature of BM biopsies may 
further limit their use for wider clinical applications. For these reasons, alternative 
sources to isolate MSC have been exploited in recent years; in this regard, much attention 
has been paid to adipose tissue because it represents an abundant and accessible source of 
adult stem cells satisfying the criteria of MSC (Dominici et al.,’06). It has been estimated 
that the frequency of ASC in collagenase-digested adipose tissue is about 500-fold higher 
than in freshly isolated BM cells (Zuk et al.,’02; Fraser et al.,’06). 
Moreover, the most important features of adipose tissue as a cell source might be the 
relative expandability of this tissue and the consequent ease with which it can be obtained 
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in relatively large quantities with minimal risks (Lin et al.,’08). In the present study, we 
show that ASC have a significant beneficial effect on chronic EAE not only when 
administered in the pre-clinical phase of disease, but also when injected after disease 
entered an irreversible clinical course, thus displaying a true therapeutic effect. In both 
cases, the amelioration of clinical scores was accompanied by a strong reduction of spinal 
cord inflammation as well as of demyelination and axonal damage in EAE lesions. Our 
results show that these cells exerted their beneficial effects by acting simultaneously in 
two distinct sites: lymphoid organs and inflamed CNS. Similarly to BM-MSC, ASC 
induced dramatic changes on antigen-specific T cells in vitro, with dose-dependent 
inhibition of their proliferation and modulation of cytokine secretion. The comparison of 
the influence of ASC on the immune system in the preventive and therapeutic protocol 
provided relevant information regarding the timing of immune activation and ASC 
administration in vivo. We show that the migration to lymph nodes of ASC was 
particularly high when administered shortly after the induction of the autoimmune 
response, whereas it was significantly lower when injected in mice with established 
disease. This preferential lymphoid migration resulted in a strong anti-proliferative effect 
and broad inhibition of both pro- and anti-inflammatory cytokine production by ASC 
injected only in the pre-clinical phase of disease. Translating these results in human 
patients, we may hypothesize that ASC-induced immune suppression will be effective 
only immediately after the immune activation occurs, i.e. in a pre-clinical phase. 
Interestingly, we provided evidence that ASC injected in mice with established disease 
induced a Th2-type shift of antigen-specific CD4 T cells in lymph nodes supporting 
recent results obtained with human BM-MSC in chronic EAE (Bai et al.,’09). 
The knowledge of the molecular mechanisms controlling ASC-based therapy is of critical 
importance in the prospective of potential future applications of ASC in humans. The 
characterization of the molecular mechanisms involved in the immune modulation and 
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those sustaining ASC homing into the CNS during EAE/MS represent an important 
contribution to the understanding of ASC tissue-specific delivery. However, the 
mechanisms involved in the migration of MSC (of any origin) into the brain are largely 
unknown.  
In addition to their immune modulatory activity shared with BM-MSC, our results 
suggest that the beneficial effect of ASC on chronic EAE relies also on the ability to 
penetrate into the inflamed CNS, due to the expression on a relevant ASC subset of 
activated α4β1 integrin, a key adhesion molecule involved in leukocyte and stem cell 
migration into the inflamed CNS (Pluchino et al.,’05). By flow cytometry, we 
demonstrated the presence on a subset of ASC of α4 integrin, which forms with β1 
integrin, constitutively present on ASC, the very late activation antigen 4 (VLA-4) which 
is the counter-ligand of VCAM-1, highly expressed on brain endothelium. Intravital 
microscopy experiments confirmed that the interaction of ASC with inflamed brain 
endothelium was through a VLA-4-dependent mechanism. Moreover, bioluminescence in 
vivo assay definitely demonstrated that ASC display α4 integrin-dependent migration in 
inflamed CNS, suggesting that adipose tissue may represent a valuable source of stem 
cells able to cross BBB and exert their action into the inflamed CNS. 
The analysis of distribution of GFP+ ASC in EAE mice injected either before or after 
disease onset indicates that these cells, in addition to migrate into lymphoid organs, were 
able to penetrate in the inflamed spinal cord and persist there up to three months, thus 
suggesting long-lasting effects in target tissues. The persistence of ASC up to 75 days 
after i.v. injection has been already described in previous studies (Meyerrose et al.,’07). 
In our model, chronic inflammation and expression of VCAM-1 on brain endothelium in 
MOG-induced EAE may help to continuously recruit ASC expressing α4 integrin from 
the blood.  
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We then asked whether and how ASC could have a neuro-regenerative effect in EAE 
spinal cord. In this regard, ASC may exert a beneficial effect participating to 
remyelination by either differentiating into mature oligodendrocytes able to form new 
myelin or indirectly by promoting the survival and proliferation of endogenous 
precursors cells. A direct participation of ASC to remyelination seems unlikely, since the 
proportion of GFP+ cells expressing PDGFαR in EAE lesions of both protocols was 
comparable to that observed in ASC cultures before injection. Another evidence pledging 
against a direct neuro-regenerative effect of ASC came from the analysis of the markers 
of mature glia expressed by ASC in situ, which revealed that only a very limited 
proportion of GFP+ ASC acquired the phenotype of mature oligodendroglial cells. In 
particular, less than 2% of O4+ oligodendrocytes derived from ASC at all time points 
investigated, a proportion that probably does not significantly contribute to the process of 
remyelination. Although we did not observe any binucleated GFP+ cells expressing 
markers of mature glia in our samples, we were not able to establish whether the 
expression of neural markers on such limited ASC sub-population in EAE spinal cord 
reflected a process of true differentiation towards a glial phenotype or rather derived from 
a process of cell fusion, as seen in other experimental conditions (Spees et al.,’03). 
Thus, the levels of engraftment of ASC and the lack of relevant neural differentiation of 
ASC do not explain the clinical and histological effects observed. In this regard, it is 
conceivable that ASC may mediate their beneficial effects into target tissues by complex 
paracrine and autocrine mechanisms. Several observations support the hypothesis that 
stem cells may display a valuable influence on host tissues by releasing a large number of 
trophic factors in response to injury and that the secretion of these bioactive factors can 
profoundly influence local cellular dynamics (Caplan et al.,’09). Neurotrophic factors 
constitute a family of polypeptides supporting neuronal maturation and specification 
during development as well as modulation of axonal growth, plasticity, and 
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neurotransmission throughout adulthood (Crisostomo et al.,’08). Several factors are 
known to be involved in neurogenesis: NGF, BDNF, neurotrophin-3, CNTF, VEGF, 
bFGF, PDGF-AB, erythropoietin and BMI-1. It has been demonstrated that indeed the 
implantation of MSC in the CNS induced a generalized increase in expression of all these 
chemokines, resulting in the stimulation, migration and proliferation of the endogenous 
NSC (Munoz et al.,’05). In line with these observations, Zhang and colleagues have 
observed that BM-MSC treatment increased in the CNS of EAE mice the expression of 
BDNF, which supports neuronal survival, regulates neurotransmitter release and 
remyelination (Zhang et al.,’05). Experimental evidence indicates that other factors may 
be directly involved in remyelination pathways: FGF-2 and IGF-I are mitogens for 
oligodendrocytes precursors and regulate their differentiation and maturation (Goddard et 
al.,’99); PDGF-AB mediates glial cells proliferation and differentiation, in addition to 
sustain neuronal survival and regeneration (Lachapelle et al.,’02); finally, VEGF, first 
characterized as an angiogenic factor, is known to increase axonal outgrowth, block 
neuronal apoptosis and promote neurogenesis (Lunn et al.,’09). 
In addition to the effects exerted to local cellular dynamics, growth factors could 
orchestrate migration, survival, self-renewal and differentiation of exogenous stem cells 
(Boucherie et al.,’09; Zaragosi et al.,’06). Here we found that in basal condition ASC 
were able to secrete large amount of IGF-I and VEGF and considerable quantities of 
BDNF, PDGF-AB and FGF-2, all factors well known to activate endogenous neural 
progenitors. 
In addition to promote the homing of ASC, we speculate that chronic inflammation might 
be responsible also for the prolonged survival of ASC in inflamed spinal cord. 
Interestingly, we found that these cells after stimulation with TNF-α produce increased 
amount of VEGF, FGF-2 and PDGF-AB as compared to basal condition, all factors 
known to promote MSC self-renewal (Zaragosi et al.,’06; Wang et al.,’06). In addition to 
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ASC, activated microglia present in active EAE lesions are also known to produce bFGF 
(Liu et al.,’98). From these observations, it is conceivable that the local inflammatory 
environment supports the prolonged survival of ASC within EAE lesions. These results 
indicate that a cross-talk between neural cells and ASC occurs in inflamed CNS, resulting 
in a positive loop resulting in a positive effect on both inflammation and neuro-
regeneration.  
Overall, our results indicate that the main mechanism responsible for the 
neuroregenerative effect in chronic EAE is a robust activation of endogenous progenitors 
in EAE lesions, which probably accounted for the process of remyelination. Indeed, the 
number of endogenous oligodendrocyte precursors (GFP-/PDGFαR+) was significantly 
higher in ASC treated animals in comparison to control EAE.  
Regarding the molecular mechanism involved in the cross-talk between ASC and 
oligodendroglial precursors, MSC are known to produce a variety of neurotrophic factors 
with relevant effects on NPC proliferation, migration and differentiation (Caplan et 
al.,’06; Rivera et al.,’06; Crisostomo et al.,’06). Here we show that ASC are able to 
secrete VEGF, IGF-I, bFGF, PDGF-AB and BDNF, all factors strongly supporting the 
process of oligodendrogenic differentiation. In fact, a key role for these factors in the 
amelioration of EAE observed in our experiments is also suggested by two studies in 
which the delivery of bFGF or BDNF induced a beneficial effect of clinical and 
pathological scores in EAE together with increase of mature oligodendrocyte and their 
progenitors in EAE model (Ruffini et al.,’01; Lachapelle et al.,’02; Zhang et al.,’04).  
In conclusion, our results show that ASC produce a beneficial effect in chronic EAE by a 
bimodal mechanism, through suppression of the autoimmune response in early phases of 
disease and promotion of Th2-polarized immune response as well as through the 
activation of local neuro-regeneration by endogenous progenitors in animals with 
established disease. Our data show that ASC have relevant therapeutic potential in an 
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animal model of chronic MS and might represent a valuable tool for stem cell-based 
therapy in chronic inflammatory diseases of the CNS. The persistence of ASC in EAE 
lesions, together with the beneficial effect displayed in the therapeutic protocol in chronic 
EAE, when clinical and pathological signs are irreversible, may have important 
implications for the future therapeutic use of ASC also in other chronic, non-
inflammatory CNS diseases, where the recruitment of local progenitors is warranted. 
Prompted by these results, we decided to evaluate the beneficial effect of ASC in the 
experimental model of an adult-onset and progressive degenerative disorder of the CNS, 
the amyotrophic lateral sclerosis  (ALS). ALS is a chronic neurological disease 
characterized by diffuse neurodegeneration which affects upper and lower motor neurons, 
resulting in paralysis and death. The vast majority of ALS are sporadic, only 10% are 
familial (FALS) and about 20% of FALS are due to the mutation in the gene encoding 
Cu/Zn superoxide dismutase (SOD)1. Transgenic mice over-expressing human SOD1 
carrying a Gly93-Ala mutation provide a widely used model for FALS. Preliminary 
results showed that, although no survival improvement was observed, animals injected 
with ASC at the onset of disease sustained significant higher behavioral performance as 
compared to controls for almost 7 weeks after injection. Moreover, ASC penetrated and 
survived into spinal cord up to 2 months but did not expressed neural and glial markers. 
These results induce us to speculate on the possible neuroprotective role of ASC through 
the release of trophic factors like VEGF, IGF-I, BDNF and FGF-2, rather than a direct 
trans-differentiation of injected cells. 
The results obtained in EAE model and the preliminary data in ALS model demonstrated 
that ASC could penetrated into damaged CNS due to the expression of VLA-4, secrete a 
vast panel of neurotrophic factors, resulting in the proliferation of endogenous 
oligodendrocyte precursors in the EAE model, in the sustainance of motorneurons in the 
ALS model as well as in the self-renewal of exogenous stem cells (Figure 32).   
 68 
                            
          
          Figure 32: Molecular mechanisms underlying the beneficial effect of ASC 
 
The convincing results obtained in EAE and the encouraging preliminary data from ALS 
models strongly indicate that, before considering their use in human patients, adult stem 
cells need to be well characterized for their adhesion molecule profile and for their 
capacity to secrete a broad range of neurotrophins. On this basis, we believe that ASC 
may represent a valuable therapeutic approach not only for autoimmune but also for 
progressive neurodegenerative disorders of CNS and could be considered an elective 
strategy for future clinical trials in human patients affected with a wide range of 
neurological disorders. 
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